Cytomx Therapeutics Stock Buy Hold or Sell Recommendation
| CTMX Stock | USD 1.04 0.05 4.59% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding CytomX Therapeutics is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell CytomX Therapeutics given historical horizon and risk tolerance towards CytomX Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for CytomX Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out CytomX Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide. In addition, we conduct extensive research on individual companies such as CytomX and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards CytomX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
CytomX |
Execute CytomX Therapeutics Buy or Sell Advice
The CytomX recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on CytomX Therapeutics. Macroaxis does not own or have any residual interests in CytomX Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute CytomX Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
CytomX Therapeutics Trading Alerts and Improvement Suggestions
| CytomX Therapeutics generated a negative expected return over the last 90 days | |
| CytomX Therapeutics has some characteristics of a very speculative penny stock | |
| CytomX Therapeutics has high historical volatility and very poor performance | |
| CytomX Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 101.21 M. Net Loss for the year was (569 K) with profit before overhead, payroll, taxes, and interest of 53.16 M. | |
| CytomX Therapeutics currently holds about 194.29 M in cash with (56.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 73.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: CytomX Therapeutics SWOT analysis biotech stocks potential in cancer treatment |
CytomX Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. CytomX analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. CytomX analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
CytomX Therapeutics Returns Distribution Density
The distribution of CytomX Therapeutics' historical returns is an attempt to chart the uncertainty of CytomX Therapeutics' future price movements. The chart of the probability distribution of CytomX Therapeutics daily returns describes the distribution of returns around its average expected value. We use CytomX Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of CytomX Therapeutics returns is essential to provide solid investment advice for CytomX Therapeutics.
| Mean Return | -0.15 | Value At Risk | -5.17 | Potential Upside | 5.00 | Standard Deviation | 3.29 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of CytomX Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
CytomX Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as CytomX Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading CytomX Therapeutics back and forth among themselves.
| Shares | Rtw Investments, Llc | 2024-06-30 | 1.2 M | Renaissance Technologies Corp | 2024-06-30 | 1.2 M | Superstring Capital Management Lp | 2024-06-30 | 1.2 M | Blackrock Inc | 2024-06-30 | 1.1 M | Geode Capital Management, Llc | 2024-06-30 | 769.5 K | Two Sigma Investments Llc | 2024-06-30 | 661.9 K | Adar1 Capital Management Llc | 2024-06-30 | 572.2 K | Citadel Advisors Llc | 2024-06-30 | 494.6 K | Sei Investments Co | 2024-06-30 | 382.7 K | Tang Capital Management Llc | 2024-06-30 | 7.8 M | Hhg Plc | 2024-06-30 | 6.3 M |
CytomX Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 19.9M | (11.3M) | (11.1M) | 11.6M | 13.4M | 14.1M | |
| Change In Cash | (59.2M) | 3.4M | 13.7M | (11.9M) | (176.5M) | (167.7M) | |
| Free Cash Flow | (144.0M) | 3.0M | (120.6M) | (112.5M) | (56.9M) | (54.0M) | |
| Depreciation | 2.6M | 2.6M | 2.7M | 2.4M | 2.2M | 2.0M | |
| Other Non Cash Items | 1.6M | 2.9M | 3.1M | 3.6M | 27.4M | 28.8M | |
| Capital Expenditures | 3.5M | 2.3M | 1.6M | 1.7M | 840K | 798K | |
| Net Income | (102.2M) | (32.9M) | (83.6M) | (99.3M) | (569K) | (597.5K) | |
| End Period Cash Flow | 189.3M | 192.8M | 206.4M | 194.6M | 17.2M | 16.3M | |
| Investments | 9.7M | 83.2M | (16.4M) | 24.1M | (63.7M) | (60.5M) | |
| Change To Netincome | 16.9M | 20.7M | 14.8M | 13.2M | 15.1M | 14.7M | |
| Change Receivables | 10.0M | 84K | (785K) | 8K | 9.2K | 9.7K |
CytomX Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to CytomX Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that CytomX Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a CytomX stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.32 | |
β | Beta against Dow Jones | 1.02 | |
σ | Overall volatility | 3.34 | |
Ir | Information ratio | -0.1 |
CytomX Therapeutics Volatility Alert
CytomX Therapeutics exhibits very low volatility with skewness of 0.85 and kurtosis of 1.93. CytomX Therapeutics is a potential penny stock. Although CytomX Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in CytomX Therapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on CytomX instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.CytomX Therapeutics Fundamentals Vs Peers
Comparing CytomX Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze CytomX Therapeutics' direct or indirect competition across all of the common fundamentals between CytomX Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as CytomX Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of CytomX Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing CytomX Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare CytomX Therapeutics to competition |
| Fundamentals | CytomX Therapeutics | Peer Average |
| Return On Equity | -54.75 | -0.31 |
| Return On Asset | 0.0233 | -0.14 |
| Profit Margin | 0.11 % | (1.27) % |
| Operating Margin | 0.12 % | (5.51) % |
| Current Valuation | (44.19 M) | 16.62 B |
| Shares Outstanding | 78.12 M | 571.82 M |
| Shares Owned By Insiders | 1.00 % | 10.09 % |
| Shares Owned By Institutions | 72.58 % | 39.21 % |
| Number Of Shares Shorted | 5.67 M | 4.71 M |
| Price To Earning | (11.41) X | 28.72 X |
| Price To Book | 5.04 X | 9.51 X |
| Price To Sales | 0.64 X | 11.42 X |
| Revenue | 101.21 M | 9.43 B |
| Gross Profit | 53.16 M | 27.38 B |
| EBITDA | (4.31 M) | 3.9 B |
| Net Income | (569 K) | 570.98 M |
| Cash And Equivalents | 194.29 M | 2.7 B |
| Cash Per Share | 2.94 X | 5.01 X |
| Total Debt | 13.97 M | 5.32 B |
| Debt To Equity | 0.67 % | 48.70 % |
| Current Ratio | 2.05 X | 2.16 X |
| Book Value Per Share | (0.30) X | 1.93 K |
| Cash Flow From Operations | (56.03 M) | 971.22 M |
| Short Ratio | 9.58 X | 4.00 X |
| Earnings Per Share | 0.15 X | 3.12 X |
| Price To Earnings To Growth | (1.80) X | 4.89 X |
| Target Price | 5.29 | |
| Number Of Employees | 120 | 18.84 K |
| Beta | 1.06 | -0.15 |
| Market Capitalization | 81.39 M | 19.03 B |
| Total Asset | 205.15 M | 29.47 B |
| Retained Earnings | (723.45 M) | 9.33 B |
| Working Capital | 27.02 M | 1.48 B |
Note: Disposition of 16535 shares by Mccarthy Sean A. of CytomX Therapeutics at 1.5749 subject to Rule 16b-3 [view details]
CytomX Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as CytomX . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About CytomX Therapeutics Buy or Sell Advice
When is the right time to buy or sell CytomX Therapeutics? Buying financial instruments such as CytomX Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having CytomX Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Mid Cap ETFs Thematic Idea Now
Mid Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Mid Cap ETFs theme has 70 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Mid Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.